- ►diabetesjournals.org CJ de Souza, M Eckhardt, K Gagen, M Dong, … - Diabetes, 2001 - Am Diabetes Assoc Obesity and dysfunctional energy partitioning can lead to the development of
insulin resistance and type 2 diabetes. The antidiabetic thiazolidinediones
shift the energy balance toward storage, leading to an increase in ... Cited by 158 - Related articles - BL Direct - All 4 versions
- ►nih.gov [PDF] A Okuno, H Tamemoto, K Tobe, K Ueki, Y Mori … - Journal of Clinical Investigation, 1998 - Am Soc Clin Investig Troglitazone (CS-045) is one of the thiazolidinediones that activate the
peroxisome proliferator-activated receptor gamma (PPARgamma), which is expressed
primarily in adipose tissues. To elucidate the mechanism by which ... Cited by 606 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org [PDF] IE Kelly, TS Han, K Walsh, ME Lean - Diabetes Care, 1999 - Am Diabetes Assoc Subjects and study design T he re were 16 male (aged 44–66 years) and 5 female
(aged 49–74 years) patients with type 2 diabetes who were re c ru ited f rom
the Diabetes Centre, Glasgow Royal I n firm a ry. Subject selection was ... Cited by 233 - Related articles - BL Direct - All 7 versions
- ►endojournals.org JM Way, WW Harrington, KK Brown, WK … - Endocrinology, 2001 - Endocrine Soc Peroxisome proliferator-activated receptor (PPAR ) agonists, including the
glitazone class of drugs, are insulin sensitizers that reduce glucose and lipid
levels in patients with type 2 diabetes mellitus. To more fully understand ... Cited by 235 - Related articles - All 2 versions
S Hallakou, L Doare, F Foufelle, M Kergoat, M … - Diabetes, 1997 - Am Diabetes Assoc Thiazolidinediones are potent antidiabetic compounds, in both animal and human
models, which act by enhancing peripheral sensitivity to insulin.
Thiazolidinediones are high-affinity ligands for peroxisome proliferator- ... Cited by 207 - Related articles - BL Direct - All 4 versions
- ►endojournals.org Y Miyazaki, A Mahankali, M Matsuda, S … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc We examined the effect of pioglitazone on abdominal fat distribution to
elucidate the mechanisms via which pioglitazone improves insulin resistance in
patients with type 2 diabetes mellitus. Thirteen type 2 diabetic patients ... Cited by 334 - Related articles - BL Direct - All 8 versions
G Boden, P Cheung, M Mozzoli, SK Fried - Metabolism, 2003 - Elsevier The current study aimed to compare the effects of treatment (2 months) with
thiazolidinediones (TZDs) and placebo on glucose and fat metabolism in patients
with type 2 diabetes (T2DM) in a crossover design. Eight patients received ... Cited by 70 - Related articles - All 10 versions
E Chaput, R Saladin, M Silvestre, AD Edgar - Biochemical and Biophysical Research …, 2000 - Elsevier Activators of peroxisome proliferator activated receptors (PPARs) are effective
drugs to improve the metabolic abnormalities linking hypertriglyceridemia to
diabetes, hyperglycemia, insulin-resistance, and atherosclerosis. We ... Cited by 132 - Related articles - BL Direct - All 6 versions
Y Mori, Y Murakawa, K Okada, H Horikoshi, J … - Diabetes Care, 1999 - Am Diabetes Assoc A thiazolidinedione derivative was dis- cove red to be a drug that impro ves
insulinresistance and was re po rted to no rmalize blood glucoselevels and impro
ve hyperinsulinemiain various diabeticanimal models ... Cited by 202 - Related articles - BL Direct - All 6 versions
T Yamauchi, J Kamon, H Waki, K Murakami, K … - Journal of Biological Chemistry, 2001 - ASBMB Peroxisome proliferator-activated receptor (PPAR) is a ligand-activated
transcription factor and a member of the nuclear hormone receptor superfamily
that is thought to be the master regulator of fat storage; however, the ... Cited by 284 - Related articles - BL Direct - All 4 versions
